You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tropomyosin receptor kinase

Showing 1 - 25 of 9,957
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Retro-/Prospective, Non-interventional, Cohort Study in Adult

Active, not recruiting
  • Solid Tumor, Adult
  • +2 more
    • Amiens, France
    • +3 more
    Jul 22, 2022

    Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

    Not yet recruiting
    • Pancreatic Ductal Adenocarcinoma
    • combination therapy with no MEKi
    • +3 more
    • (no location specified)
    Nov 29, 2022

    Liposarcoma, Metastatic Liposarcoma Trial in Boston, Saint Louis, New York (MGCD516)

    Active, not recruiting
    • Liposarcoma
    • Metastatic Liposarcoma
    • Boston, Massachusetts
    • +2 more
    Nov 23, 2022

    Called EPI VITRAKVI to Compare Treatment Results in Infantile

    Completed
    • Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
    • Infantile Fibrosarcoma
    • Larotrectinib (Vitrakvi, BAY2757556)
    • Standard of Care
    • Multiple Locations, France
      Multiple Locations
    Jan 10, 2023

    Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

    Active, not recruiting
    • Neoplasm
    • Beijing, China
    • +5 more
    Jan 31, 2023

    Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

    Active, not recruiting
    • Metastatic Breast Cancer
    • Hospitalet de Llobregat, Barcelona, Spain
    • +6 more
    Jan 23, 2023

    Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

    Recruiting
    • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
    • Topical Timolol
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 14, 2023

    NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +2 more
    • (no location specified)
    Mar 27, 2023

    Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal Trial in Los Angeles, Bethesda (Dasatinib, Ganitumab)

    Terminated
    Has Results
    • Rhabdomyosarcoma
    • +2 more
    • Los Angeles, California
    • +1 more
    Mar 17, 2022

    Solid Tumor Trial (TL118 Capsule)

    Not yet recruiting
    • Solid Tumor
    • TL118 Capsule
    • (no location specified)
    Aug 18, 2023

    Phase 1, Solid Tumor, Adult Trial in Goyang, Seongnam, Seoul (NOV1601(CHC2014))

    Completed
    • Phase 1
    • Solid Tumor, Adult
    • Goyang, Gyeonggi-do, Korea, Republic of
    • +3 more
    Sep 8, 2021

    Advanced Non Small Cell Lung Cancer Trial in Changchun, Shanghai, Hangzhou (D-0316)

    Active, not recruiting
    • Advanced Non Small Cell Lung Cancer
    • Changchun, Jilin, China
    • +2 more
    Apr 29, 2022

    Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

    Recruiting
    • Advanced Breast Carcinoma
    • +17 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    MuSK Myasthenia Gravis Trial (MuSK-CAART)

    Not yet recruiting
    • MuSK Myasthenia Gravis
    • MuSK-CAART
    • (no location specified)
    Jul 5, 2022

    Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,

    Active, not recruiting
    • Estrogen Receptor-positive Breast Cancer
    • +5 more
    • PI3K inhibitor BYL719
    • +3 more
    • Boston, Massachusetts
    • +1 more
    Oct 14, 2022

    Myasthenia Gravis, MuSK Trial in Cleveland, Philadelphia (Amifampridine Phosphate)

    Active, not recruiting
    • Myasthenia Gravis, MuSK
    • Amifampridine Phosphate
    • Cleveland, Ohio
    • +1 more
    Jul 21, 2022

    NSCLC Trial in Australia, China, Korea, Republic of (AZD9291)

    Active, not recruiting
    Has Results
    • Non-Small Cell Lung Cancer
    • Kogarah, Australia
    • +29 more
    Oct 20, 2022

    Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • Miami, Florida
      University of Miami
    Apr 12, 2023

    Metastatic Renal Cell Carcinoma Trial in France (Cabozantinib)

    Recruiting
    • Metastatic Renal Cell Carcinoma
    • Angers, France
    • +8 more
    Dec 5, 2022

    Advanced/Metastatic Solid Tumors Trial in Frankston, Nedlands, Beijing (EMB07)

    Not yet recruiting
    • Advanced/Metastatic Solid Tumors
    • Frankston, Victoria, Australia
    • +2 more
    Nov 3, 2022

    Personalised Disease Monitoring in Metastatic Breast Cancer

    Recruiting
    • Breast Cancer Metastatic
    • Estrogen Receptor-positive Breast Cancer
      • Gothenburg, Sweden
      • +6 more
      Dec 7, 2022

      Stage II Renal Cell Cancer, Stage III Renal Cell Cancer Trial (tivozanib, therapeutic conventional surgery)

      Withdrawn
      • Stage II Renal Cell Cancer
      • Stage III Renal Cell Cancer
      • (no location specified)
      Aug 11, 2022

      NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • (no location specified)
      May 23, 2023

      NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +5 more
      • Toripalimab
      • +3 more
      • Guanzhou, Guangdong, China
        Guangdong Lung Cancer Institute, Guangdong Provincial People's H
      Apr 4, 2023

      NSCLC Trial (AK119, AK112, Pemetrexed)

      Not yet recruiting
      • NSCLC
      • (no location specified)
      Nov 23, 2022